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ABSTRACT 
The QALY is an impossible construct; it defies common sense. It fails completely once we consider the axioms of fundamental 
measurement. Utilities as ordinal scales cannot be used to create QALYS. The QALY should never have been introduced to support the 
value assessment of pharmaceutical products and devices. The result is 30 years of QALY based assessments of pharmaceutical 
products and devices which are conceptually and technically wrong. They are a charade and will have contributed mistakenly to  
thousands of formulary decisions. In the search for a common metric to evaluate cost-effectiveness the impossibility of a QALY was 
overlooked. The result is a disaster, unfolding over decades. Our next steps must be to abandon the QALY paradigm and look ahead to 
a new value assessment framework. 
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INTRODUCTION 
For the past 30 years the notion of quality adjusted life years, 
the QALY, has occupied center stage in the value assessment 
literature for pharmaceutical products and devices. 
Unfortunately, in retrospect, the notion of a QALY was always 
impossible; hence the application here of the term impossible 
or I-QALY 1. It should have been dismissed, both as an imaginary 
and as an operational metric, as soon as it was proposed. The 
reason is quite simple. If you want to transform a period of time 
in a disease state to its I-QALY equivalent, years of perfect 
health, then the utility or whatever you want to call the metric 
must have ratio measurement properties. The interval scale has 
identity, magnitude and equal intervals. It supports the 
mathematical operations of addition and subtraction. A ratio 
scale satisfies all properties, supporting the additional 
mathematical operations of multiplication and division. 
Recognition and adherence to these fundamental axioms of 
measurement theory is critical if an instrument is to have any 
credibility. That is, the utility must have a true zero (i.e., no 
utility value can take negative values) and it must have a 
maximum value of unity. While, by construct, utilities have a 
ceiling at unity (1 = perfect health) there is no true zero. There 
are states worse than death; negative utility scores below the 
arbitrary 0 = death (which is arbitrary).  In the case of the most 
widely used utility scale, the EQ-5D-3L the scoring algorithm 
yield utilities in the range -0.59 to 1. If there is no true zero, the 
utility scale cannot support multiplication. End of story. The I-
QALY notion should have been smothered at birth. A utility is 
nothing more than an ordinal score. The ordinal scale does not 
have interval or ratio properties because no one developing the 
various utility scales and who then proposed creating QALYs 
had the thought of building those requirements into the scale.  
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In the physical sciences accurate measurement is the key to 
hypothesis testing and the discovery of new facts. The same 
arguments apply to the social sciences. Unfortunately, they 
appear all too often to be absent in health technology 
assessment and in the development of patient reported 
outcomes (PROMS) instruments.  A lack of attention which sets 
value assessment aside from the physical sciences, where from 
first principles instruments have to recognize these axioms 2. 
This does not mean that there have not been ongoing criticisms. 
These have ranged from critiques of the assumptions 
supporting the utility measure to the attributes covered in 
multiattribute instruments, the failure to consider dimensional 
homogeneity, and the neglect of the patient voice 3 4. Only a 
few have addressed the question of fundamental measurement 
and the fact that the various utility instruments and the 
majority of PROMS instruments support only ordinal scales 5 6 7 
8 9 10 11. As ordinal scales, none can address the question of 
therapy response. 
 
THE DISASTER UNFOLDS 
How has this I-QALY disaster come about? Basically, through 
ignorance of fundamental measurement and a belief in the 
contribution of evidence constructed to support imaginary 
claims for cost effectiveness. Over the last 30 years thousands 
of papers have been published; conferences promoted and 
seminars attended, professional groups such as the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) founded, formulary decisions made and 
patients excluded from potentially innovative therapies 
because in the 1980s no one gave a thought to the axioms of 
fundamental measurement.  This is unforgivable. Professional 
organizations such as ISPOR, numerous gatekeepers for single 
payer health systems and, in the US, the Institute for Clinical 
and Economic Review (ICER) have, possibly unwittingly, 
perpetuated the idea that utility scales, in particular the various 
multiattribute or preference generic utility systems, have ratio 
properties or can be treated as if they do; although the term 
ratio scale nor any of the other measurement scales were 
considered in terms of their limitations, a requirement to 
construct I-QALYs.  
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The I-QALY disaster can be traced back to the late 1980s with 
the focus on cost-effectiveness and how claims for competing 
products were to be presented. The decision makers were 
assumed to be single payer health systems (e.g., the National 
Health Service in England) which were charged with evaluating 
the benefits of competing products or new products versus 
standard of care. With limited resources and the possibility of 
having to ration or replace existing products, there was seen to 
be a need for a common central health planning metric. An 
obvious candidate was a generic multiattribute measure of 
quality of life (health related quality of life: HRQOL). While no 
thought was given to measurement axioms, it was assumed 
that utilities from an instrument such as the EQ-5D-3L, a 
multiattribute, multidimensional, ordinal HRQOL instrument 
could be applied. This was the fundamental error. 
 
At the same time, it was recognized that there was limited 
information to hand at the time of product approval to support 
cost-effectiveness (now cost-utility) claims; apart from limited 
modeling on the clinical trial data. Even so, cost-per-I-QALY 
claims would have been invalid; a protocol may have included 
the EQ-5D-3L (for example) as a primary end-point (most 
unlikely) but this would still preclude any I-QALY claims based 
on the timeframe of the randomized clinical trial.  
 
The answer was to create imaginary cost-effectiveness claims 
through the construction of simulated lifetime decision-
framework models. Hypothesis testing was put to one side in 
favor of the ‘approximate information’ modeling constructs 
which lacked even a semblance of empirical credibility. Their 
claims were, a major positive plus, non-evaluable, let alone 
impossible to replicate between treatment settings.  It was 
nothing more than pseudoscience; failing the demarcation test 
between science and pseudoscience. The proposed technology 
assessment models, enthusiastically endorsed by ISPOR in their 
collection of best imaginary practice monographs, joined 
intelligent design, not natural selection, in the Dover courtroom 
12. For ISPOR, the absence of evidence did not preclude 
imaginary claims being made; in fact the opposite, it was 
encouraged.  Indeed, by design, the modeled claims were 
impossible to evaluate. An enviable position: unless challenged 
on the choice of imaginary model assumptions 
recommendations for pricing and access by groups such as ICER 
in the US were inviolable.  
 
Unlike the other social sciences where the focus is on 
hypothesis testing and the discovery of new facts, emulating 
the physical sciences, the world of ISPOR, ICER and gatekeeper 
technology assessment agencies is devoted to the construction 
and marketing of fatally flawed imaginary worlds. A belief 
system, a meme, that is widely entrenched to the extent that 
thousands of researchers believe that they can ignore 
fundamental measurement (if they are aware of it) and drive 
formulary decisions, not by the discovery of new facts and the 
evaluation of hypotheses as to product performance in target 
patient populations, but by the putting to one side of the 
standards of normal science and creating imaginary evidence 
for cost-effectiveness 13. Health technology assessment is the 
only social science branch, if that is not too inappropriate a 
label, that actively promotes imaginary constructs and puts its 
faith in non-evaluable claims. Absent the standards of normal 
science: truth is consensus. Evidence for cost-effectiveness is 
invented not discovered 14. 
 
Considerable effort was devoted to justifying the construction 
of lifetime imaginary cost-per-I-QALY incremental imaginary 
claims. By the end of the 1990s and the adoption of the NICE 
reference case, which mandated manufacturer constructed 
imaginary worlds and thresholds for pricing, the paradigm was 
well entrenched 10.  Global acceptance soon followed (and 
again no mention of fundamental measurement). Promoted by 
one and two way sensitivity analyses, probabilistic sensitivity 
analyses and supplementary scenarios, the reference case 
model was accepted and endorsed by groups such as the 
Academy of Managed Care Pharmacy and the National 
Pharmaceutical Council 15. Yet no one recognized the 
fundamental and fatal flaw with the I-QALY. Individuals who 
raised the issue of the axioms of fundamental measurement for 
interpreting utilities were ignored 4 5; yet even then the 
implications of this for the I-QALY were overlooked. 
 
If you wish to measure response, then the instrument has to 
have interval and, if possible, ratio properties. Developing a 
measure through the application of classical test theory ensures 
that the resulting scale or score is nothing more than an ordinal 
scale. The endeavor falls at the first hurdle. If you want to 
measure any particular attribute or latent construct (e.g., needs 
based quality of life) then your instrument must capture those 
items that ensure it has the required unidimensional 
measurement property. The input data have to fit the 
instrument; we should not try to fit the instrument to the data. 
Hence the popularity since the 1960s of Rasch measurement 
theory and its acceptance from the early 1990s, by a few 
individuals, in technology assessment and therapy response 16. 
 
MARKETING THE I-QALY 
Basing cost-effectiveness claims on simulated lifetime 
imaginary world, driven entirely by assumption where the 
claims are impossible to evaluate empirically, offers a tempting 
target for reverse engineering claims. In the absence of the 
ability to test hypotheses where claims are credible, evaluable 
and replicable, the pseudoscience of simulated I-QALY claims 
takes center stage. In defense of the imaginary world, the key 
is the notion of ‘approximate information’. 
 
This has been clearly stated by ISPOR: leaders in the field of 
economic evaluation have long recommended that analysts 
seeking to inform resource allocation decisions approximate the 
value of interventions in terms of incremental cost-per-QALY 
gained 17. This position is endorsed by the latest Canadian 
guidelines: Economic evaluations are designed to inform 
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decisions. As such they are distinct from conventional research 
activities, which are designed to test hypotheses 18.  
 
Taking refuge in the argument that these simulated I-QALY 
models are ‘for approximate information’ is no defense. The 
term has no meaning. This is not ‘approximate information’; it 
is worse – there is no information content, there is no question 
of reducing uncertainty, because the I-QALY and cost-per-I-
QALY lifetime models are impossible fictions. The I-QALY claims 
for incremental gains, irrespective of the time frame and choice 
of assumption, are meaningless. Attempts to make I-QALY 
presentations more ‘believable’; by application of sensitivity 
analyses are equally meaningless. It is difficult to conceptualize 
the likelihood, through probabilistic sensitivity analysis, of the 
cost-effectiveness of an impossible claim. There is a 
fundamental disconnect between the standards of normal 
science and what passes for ‘standards’ in health technology 
assessment. We are dealing with constructs which fail accepted 
standards for instrument development: the emphasis on 
multiattribute composite ‘measures’ and the belief that we can 
add up any number of scores, ignoring dimensional 
homogeneity 4, and falsely accept that the resulting aggregate 
score can actually meet either interval or, more broadly, ratio 
scale properties.  
 
This brings us back to the fundamental issue: preference 
measures, such as the EQ-5D-3L are ordinal measures where a 
community survey has generated weights for the various 
responses and response patterns among the item. As the 
constructs underlying each item differ it is invalid to add these 
to give a total score. The preference weights themselves are 
ordinal measures; no thought was given to constructing interval 
scores. Adding items ignores the axioms of fundamental 
measurement as each item is an ordinal score; in aggregate it is 
still an ordinal score which cannot support either claims for 
therapy response or the construction of QALYs. It might be 
added, as an obvious conclusion, that attempts to map between 
ordinal scales to overcome data gaps  (e.g., EQ-5D-3L to EQ-5D-
5L) is a waste of time 4.  
 
Unfortunately, ‘approximate information’, opens the 
floodgates to marketing simulations with the opportunity for  
consultants developing model frameworks that support a 
client’s product. Concern with the construction of ‘favorable’ 
imaginary claims has led, inevitably, to a cadre of inquisitors 
tasked with reporting on the purity of the imaginary modeled 
claims. Academic groups in countries such as the UK and 
Australia (reporting to NICE and the Pharmaceutical Benefits 
Advisory Committee respectively) are tasked with reviewing 
models submitted to the agency to pronounce on their 
imaginary methodological purity 19 20. Inquisitors can suggest 
modifications or alternative model structures and assumptions, 
even giving a submission a good housekeeping seal of approval. 
These critiques of the submitted models illustrate the flexibility 
of these non-evaluable claims with competing model 
frameworks. Journals do not have this luxury; the peer review 
process was not intended to support this level of unbundling a 
model. Even so, it is difficult to believe that the peer review 
process overlooked the impossibility of the I-QALY, let alone the 
lack of appreciation of the standards of normal science.    
 
FIDELITY AND ISPOR CHEERS 
Beliefs must be sustained; the technology assessment meme 
must be codified and reinforced to ensure copying fidelity (e.g., 
Council of Nicaea and Nicene Creed). Practitioners building 
imaginary worlds require assurance that they are meeting 
required standards for imaginary modelling. The ISPOR CHEERS 
reporting guidance checklist provides such an assurance 21. 
Published in 2013, CHEERS (Consolidated Health Economic 
Evaluation Reporting Standards) builds on previous ISPOR 
standards, providing imaginary and I-QALY driven model 
builders with a framework for justifying their construction of 
simulated claims. Certainly a number of the questions would be 
relevant to modeled claims consistent with the standards of 
normal science, but it is clear from the context and the 
questions addressed that the primary audience is those 
creating imaginary I-QALY driven cost-outcomes claims. These 
include analysts and reviewers; indeed it is noteworthy that to 
support fidelity in imaginary model construction and 
assessment that the CHEERS checklist was distributed to 
leading journals that had (and continue) to accept cost-per-I-
QALY imaginary constructs. 
 
Given the present I-QALY critique it is worth noting that there 
is no requirement for model builders to determine whether or 
not their claims meet the standards for credibility and empirical 
evaluation. There is no discussion of instrument standards and 
the need to meet the axioms of fundamental measurement. 
The EQ-5D-3L is given as an exemplar outcome measure. In 
practical terms CHEERS is a checklist for reporting and 
reviewing imaginary economic evaluations. A tool designed to 
reinforce existing imaginary modeling standards proposed by 
ISPOR. As would be expected there is no discussion of claims 
evaluation in target treating populations. Nor should we expect 
this as it is simply a checklist for the imagination. The reporting 
of results section is focused on the model as a self-referential 
closed system: study parameters (reporting values, ranges, 
references and parameter probability distributions), 
incremental costs and outcomes, the characterization of 
uncertainty and heterogeneity. All that would be needed to 
clarify the intent of the CHEERS checklist would be to ask 
whether the economic evaluation was designed to propose 
credible and empirically evaluable claims. This would, perhaps 
unfortunately, put the fox in the imaginary henhouse. 
 
THE WORLD TURNED UPSIDE DOWN 
But the hens are safe. There is no doubt as to the acceptance of 
the I-QALY. As an indication, a Pub Med count on the keywords 
“Cost AND QALY” [accessed 29 July 2020] yielded a total of 
16,378 citations with hundreds of citations for a sample of 
individual journals (Table 1). The majority of these published in 
the last 15 years with an almost exponential growth, 
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particularly for the health technology journals such as 
Pharmacoeconomics which is in pole position.  
 
Table 1 
PubMed Citations for “Cost and QALY” 
Total count 16,378 
PharmacoEconomics 552 
Value in Health 519 
Journal of Medical Economics 369 
British Medical Journal 374 
Lancet 193 
Journal of the American Medical Association 164 
New England Journal of Medicine 124 
 
 
To supporters of the I-QALY and approximate information this 
is a sure and certain sign of the acceptance of their paradigm; 
to others who are aware of the limitations imposed by the 
axioms of fundamental measurement and the pre-eminent role 
of the scientific method, this is an indictment. How so many 
could engage with a pseudoscientific belief system is testament 
to the willingness to engage with a belief system founded on 
ignorance. A situation which is certainly not unusual with fringe 
religions and associations. 
 
Unrecognized after some 30 years of I-QALY application, the 
incontrovertible fact is that generic multiattribute instruments, 
the standard gamble and time trade off, together with virtually 
all PROMS yield ordinal scores. This is dictated by the axioms of 
fundamental measurement. The even more unfortunate 
corollary is that the implicit belief that the various instruments 
have ratio properties can be simply dismissed. The logical 
conclusion is that the I-QALY is an impossible mathematical 
construct. This is, to say the least, an embarrassing situation. 
How are the erstwhile supporters of the I-QALY and the cost-
per-incremental I-QALY value assessment framework to 
respond?  
 
This ‘embarrassment’ is made the more concerning when the 
sheer number of studies is considered. Although the PubMed 
count of 16,378 could be refined by a more rigorous systematic 
review (which seems hardly worth the effort) it is difficult to 
think of another example of misapplied science that reaches 
this publication magnitude. The willingness, without question, 
of analysts to accept the I-QALY is astounding; but who is to give 
the bad news? Journal editors are in an invidious position with 
the ‘leading’ journals in health technology assessment such as 
Pharmacoeconomics with 552 ‘hits’ having to provide some 
explanation. The same applies to the leading medical journals. 
 
DEFENDING THE I-QALY 
Without doubt, after 30 years there will be sustained efforts to 
defend the I-QALY.  The belief system, or technology 
assessment meme, is well entrenched.  Unscrambling and 
rejecting such a belief system, a belief in the merits of 
impossible (not approximate) information, will not be easy. 
After 30 years the appeal and retreat to ‘truth is consensus’ will 
lead to the wagons being circled. No one, let alone those 
experiencing 30 years of indoctrination and advocacy, wants to 
be told that the leaders in the field are wrong.  ISPOR, which 
has a lot to lose, may mount a save the I-QALY crusade. Critics 
will be pilloried; journal articles and letters to the editor will be 
summarily rejected, leaders in the field of technology 
assessment will redouble and double again efforts to assure 
their followers and clients in industry and technology 
assessment that the mystery of the I-QALY is safe. Advocates 
could argue that, yes, it might need modifying and embedding 
within other value assessment frameworks, so that the efforts 
of the last 30 years are seen as a sure stepping stone to a more 
inclusive, even patient centric, use of modeled claims in 
imaginary formulary decisions.  
 
After all, it might be argued, an approximate assumption driven 
information framework supporting non-evaluable claims, 
blessed by professional groups and leaders in the field, provides 
a sure and certain hope for an I-QALY future.  The issue of 
fundamental measurement will be just a minor issue which, by 
assumption, can be put to one side. Welcome to a new branch 
of science fiction. It is on this rejection of normal science that 
health technology assessment is built. 
 
But perhaps the death will be over quickly. After all, the 
technology assessment paradigm only survives if the customer, 
such as a formulary committee, believes it has merit. Once 
doubts set in, with formulary committees and patient advocacy 
groups pointing out the manifest deficiencies of the I-QALY 
paradigm, a tipping point will have been reached. If so, this 
raises the questions of explaining how this unfortunate state of 
affairs was maintained and how the process of re-education 
might be initiated. 
 
Paradigm shifts are not new in the history of science, or in the 
social sciences. Indeed, the disputes can become extended (and 
noisy) with academic groups and journal editors taking sides. 
The present case does not bode well. It is not the question of 
special and general relativity supplanting Newtonian 
mechanics. As Brian Greene points out: When quantum 
mechanics came along, Newton’s edifice was not dismantled. It 
was renovated. Quantum mechanics provided a new foundation 
that deepened the reach of science and gave the Newtonian 
structure a fresh interpretation 22.  In the I-QALY case it is not a 
question of a fresh interpretation within a successor paradigm; 
the I-QALY edifice has to be rejected. It cannot be renovated. 
We have a situation where the post-I-QALY (or non-QALY) 
paradigm for assessing the value of competing pharmaceutical 
products and devices actually replaces the I-QALY paradigm. 
This seems unavoidable: there is not much room, if any, for 
maneuver. As the I-QALY paradigm is built on a denial of the 
standards of normal science including a belief that it is possible 
to assume that an ordinal scale can have ratio properties, then 
this will be totally at odds with a new value assessment 
paradigm that recognizes these axioms. There are just too many 
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fundamental errors. We cannot build on an impossible 
construct despite how many believe in it. Real world evidence 
must replace imaginary lifetime world created evidence. 
 
The great I-QALY disaster is not just the result of a minor 
academic oversight. The implications go far deeper. For 30 
years formulary decisions have been influenced, if not dictated, 
by a cost-per I-QALY construct which is mathematically 
nonsensical. Thresholds have been touted as the last word in 
value assessment. Pricing negotiations have been driven by an 
imaginary construct; access to care has been similarly blighted. 
Why? Because ‘leaders’ in the field determined that creating 
imaginary evidence for cost-effectiveness claims trumps real 
world evidence. The last 30 years could have provided the 
opportunity to develop evidence platforms to support real 
world evidence cost-outcomes claims across disease areas; that 
opportunity has been squandered by the obsession with 
reference case imaginary worlds.  
 
Although the data are limited, there is evidence pointing to an 
unfortunate increase in the acceptance of I-QALY based ICER 
recommendations in the formulary decision process. The 
concern is that in accepting ICER recommendations to support 
pricing and access protocols, the decision makers have no idea 
of the basis on which ICER arrived at these conclusions. Few 
formulary or more broadly health decision makers, have the 
skills necessary to evaluate ICER modeled claims. The reference 
case framework is a black box. Questions regarding the 
reference scientific status and the impossibility of creating I-
QALYs in an imaginary pseudoscientific simulation are ignored; 
none have the skills to argue the case for its rejection. This lack 
of awareness is further compounded by the failure to 
recognize, or even acknowledge, the limitations imposed by the 
axioms of fundamental measurement on instrument 
development.  
 
In this situation manufacturers will be rightly concerned that 
they are being shortchanged. Introducing recommendations for 
pricing and product access into formulary negotiations that 
have no basis in reality is hardly a comfortable situation. To 
what extent do formulary committees give weight to the I-QALY 
construct? Will they ask ICER to renounce publicly? What 
recourse do manufacturers have if they fail to convince 
formulary committees that the I-QALY modeling is useful and 
not an analytical dead end? More troubling are the concerns of 
patients and providers. Are they being denied access to new 
and innovative therapies on the basis of an imaginary and 
impossible simulation model? Are health care decision makers 
being misled? The problem with ICER is that in renouncing five 
years of evidence report modeling and claims, the business case 
collapses. ICER has nowhere else to go. 
 
CONCLUSIONS 
The fact that utilities are ordinal scales is incontrovertible. 
There is no way they could be anything other than ordinal 
scales; by design they cannot support cost-per-QALY claims and 
threshold criteria for pricing and access. If there had been an 
intention to generate utilities with interval, if not ratio 
properties this should have been central to the development of 
the various systems; it was not. The meaningless term ’QALY’ 
should be put to one side; excised from the technology 
assessment lexicon. Certainly, focus on the notion of a latent 
construct that we can call quality of life. As a measure of 
response there are now a number of examples of needs-based 
quality of life latent measures that meet the standards for 
fundamental measurement 23 24.  Abandoning the existing 
technology assessment paradigm clears the field for a new 
paradigm, a patient centric, disease specific paradigm that 
recognizes the need for meeting the fundamental axioms of 
measurement theory. Patients are the principal beneficiary, 
including caregivers, from new and innovative therapies. This 
should not be denied.  We can abandon the absurdity of 
lifetime imaginary constructs and the creation of impossible 
information. Our attention needs to be on patients and 
caregivers. Once this evidence is before us, we can discuss 
pricing and access; these discussions must be driven by real 
world evidence, not imaginary and impossible evidence for 
comparative claims. 
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